Nature Communications
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
July, 2024
July 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jun
Nature Communications
Jul 25, 2024, 12:07 |
Insight
Sonia Guedan: CAR affinity modulates CAR-T cells' sensitivity to PD-1/PD-L1 inhibition
Sonia Guedan, shared a post on X about a recent paper titled "CAR affinity modulates the…
Jul 25, 2024, 01:14 |
Insight
How cancer cells use antioxidants and how this relates to diseases, including cancer - Wilmot Cancer Institute
Isaac Harris, Assistant Professor at UR Medicine, shared a post on X about a recent…
Jul 22, 2024, 20:26 |
Insight
How tumor biology impacts Patritumab deruxtecan's efficacy in early breast cancer
Sonia Guedan, Cancer Immunologist at Hospital Clinic Barcelona, posted on X: "Our colleague Aleix Prat's…
Jul 18, 2024, 09:35 |
Insight
ctDNA variant-specific differences as potential mPDAC prognostic biomarker - PICI
Parker Institute for Cancer Immunotherapy (PICI) shared a post on X about a recent paper titled…
Jul 16, 2024, 20:12 |
Insight
Hao Yin: SenNet recommendations for detecting senescent cells in different tissues
Hao Yin, Cardiovascular biologist at Robarts Research Institute, shared on X: “SenNet Consortium recommendations for…
Jul 14, 2024, 22:08 |
Blog
Jessie Guo: G6PD is essential for KL but not KP lung tumorigenesis
Jessie Guo, Associate Professor at Rutgers Cancer Institute of New Jersey, shared on X: "Check…
Jul 14, 2024, 07:19 |
Insight
Immuno-oncologic profiling of pediatric brain - Hawkins Lab
Hawkins Lab shared a recent paper on X, titled "Immuno-oncologic profiling of pediatric brain tumors reveals…
Jul 2, 2024, 04:16 |
Insight
Olivier Calvayrac: TT-derived drug-tolerant (DT) lung cancer cells are vulnerable to FTIs
Olivier Calvayrac, Research Scientist at the Toulouse Cancer Research Center, shared a post on X…
Jun 21, 2024, 11:16 |
Insight
Paolo Tarantino: Phase 1 trial of the MMAF-based, HER2-targeting ADC FS-1502 published in Nature Communications
Paolo Tarantino shared on X/Twitter: "Phase 1 trial of the MMAF-based, HER2-targeting ADC FS-1502 published…
Jun 21, 2024, 04:15 |
Insight
Biagio Ricciuti: Fusion partners and chromosomal breakpoints of oncogenic fusions are not stochastic
Giannis Mountzios, Medical Oncologist at the Department of Medical Oncology in the Air Force General…
May 28, 2024, 14:49 |
Career
Laura Sánchez Burgos: Nature Communications is looking for another Associate or Senior Editor with a Cancer Genomics background
Laura Sánchez Burgos, Associate Editor at Nature Communications, shared on X: "My team at Nature…
May 24, 2024, 14:50 |
Insight
A new paper on VC-resist glioblastoma cell state out in Nature Communications
A groundbreaking new open-access paper was published in the prestigious journal, Nature Communications, titled "VC-resist…
May 20, 2024, 14:10 |
Insight
Miguel Bronchud: A UK large study has discovered multiple associations between blood proteins and cancer risk
Miguel Bronchud, Co-Founder of Regenerative Medicine Solutions, shared on LinkedIn: "Hope for better selecting individuals…
May 18, 2024, 14:15 |
Insight
Tracey O’Brien: Melanoma Institute Australia is moving the dial in understanding and personalizing treatment melanoma for AYA
Tracey O’Brien shared a post by Melanoma Institute Australia on LinkedIn, adding: "The most common…
May 14, 2024, 08:56 |
Insight
UCLA: Adding immune-boosting agent to personalized cancer vaccine supercharges the body's immune defense against malignant brain tumors
The combination of poly-ICLC with an immunotherapy vaccine utilizing dendritic cells is a promising approach…
May 13, 2024, 13:41 |
Insight
Innovative stem cell model provides insight into childhood cancer origins
Researchers from the University of Sheffield and St. Anna Children’s Cancer Research Institute have created…
May 6, 2024, 07:29 |
Insight
Center for Cancer Immune Therapy - Molecular patterns of resistance to immune checkpoint blockade in melanoma
Center for Cancer Immune Therapy shared on LinkedIn: "Molecular patterns of resistance to immune checkpoint…
May 1, 2024, 10:36 |
Opinion
Kai-Cheng Hsu: How polygenic scores can enhance disease prediction
Kai-Cheng Hsu shared a post on LinkedIn: "I am thrilled to announce that our groundbreaking research…
May 1, 2024, 01:32 |
Blog
Kai-Cheng Hsu: Our groundbreaking research on the ‘Utility of polygenic scores across diverse diseases in a hospital cohort for predictive modeling
Kai-Cheng Hsu, Chief Medical Officer of Biomedical Technology and Device Research Laboratories in Industrial Technology…
May 1, 2024, 01:17 |
Blog
Jun Qi: Our article on EP300/CBP bromodomain inhibition in Group 3 medulloblastoma is now published
Jun Qi, Assistant Professor of Medicine at Dana-Farber Cancer Institute, shared a post on LinkedIn:…
Apr 29, 2024, 00:46 |
Blog
Sonia Guedan: How CAR affinity influences CAR-T cell sensitivity to PD1/PD-L1 inhibition
Sonia Guedan, Cancer Immunologist at Hospital Clinic Barcelona, posted on X/Twitter: "Excited to share that…
Apr 2, 2024, 05:37 |
Drugs
Paolo Tarantino: The OXEL trial is out on Nature Communications
Paolo Tarantino, Medical Oncologist and Research Fellow at Dana-Farber Cancer Institute, shared a post on…
Mar 15, 2024, 18:24 |
Drugs
Paolo Tarantino: Final analysis of the PEONY phase 3 trial
Paolo Tarantino, Medical Oncologist and Research Fellow at Dana-Farber Cancer Institute, shared a post on…
Feb 8, 2024, 21:20 |
Blog
Justin Stebbing: The first time invariant natural killer cells has ever been used as a cell therapy
Justin Stebbing shared a post on LinkedIn: “Super-thrilled to see our paper finally out in Nature…
Feb 2, 2024, 12:11 |
Blog
Yousef Zakharia: Combining hypomethylating agent guadecitabine and IO in ccRCC
Yousef Zakharia, Associate Professor of Medicine at The University of Iowa shared a post on…
Nov 18, 2023, 16:10 |
Insight
Justin Stebbing: How older first-time pregnancy contributes to breast cancer
Justin Stebbing shared on LinkedIn Society of Physician Entrepreneurs (SoPE) group: "Super thrilled that the…
Sep 8, 2023, 19:03 |
Insight
Angela Mastronuzzi: Our Ospedale Pediatrico Bambino Gesù team's recently published paper with Nature Communications by Nature Portfolio is out.
Angela Mastronuzzi, Head of Neuro-Oncology Unit at Bambino Gesù Children's Hospital, recently posted on LinkedIn:…
Sep 8, 2023, 18:21 |
Insight
Justin Stebbing: Why some women who have had children might have different risks for breast cancer compared to those who haven't
Justin Stebbing, shared on LinkedIn, "Thank you to my amazing team, special thanks to Biancastella…
Sep 5, 2023, 17:53 |
Insight
Ola Landgren: In this tweetorial, we delve into a groundbreaking study on multiple myeloma and the immune microenvironment.
Ola Landgren, Professor of Medicine, Chief of the Myeloma Division, and Leader of the Experimental…
Sep 5, 2023, 17:07 |
Insight
A new ICR study has provided insights into an important biological mechanism that supports survival of aggressive, hard-to-treat cancers. - The Institute of Cancer Research
All:
30
Posts:
1 - 100
The largest philanthropic partnership in The V Foundation’s history - Dolphins Cancer Challenge
Glecirasib: A Promising Novel KRAS G12C Inhibitor in Clinical Development
How the Médecins Sans Frontières Journal Inspired a Lifetime of Humanitarian Service: Paul Spiegel
OncoDaily Party and Yvonne Award Photos - Part 1
Michael Douglas: The Untold Story of His Battle Against Cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube